Diane Descamps to HIV-1
This is a "connection" page, showing publications Diane Descamps has written about HIV-1.
Connection Strength
2.036
-
Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen. J Antimicrob Chemother. 2018 04 01; 73(4):1039-1044.
Score: 0.246
-
Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations. Viruses. 2018 01 18; 10(1).
Score: 0.242
-
Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence? J Antimicrob Chemother. 2020 01 01; 75(1):183-193.
Score: 0.069
-
New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017. Euro Surveill. 2019 Sep; 24(39).
Score: 0.068
-
New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations. J Antimicrob Chemother. 2019 07 01; 74(7):2019-2023.
Score: 0.067
-
Concentration-response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients. J Antimicrob Chemother. 2019 07 01; 74(7):1992-2002.
Score: 0.067
-
HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen. J Antimicrob Chemother. 2019 06 01; 74(6):1679-1692.
Score: 0.067
-
Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France. J Antimicrob Chemother. 2019 05 01; 74(5):1417-1424.
Score: 0.066
-
Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients. J Antimicrob Chemother. 2019 05 01; 74(5):1368-1375.
Score: 0.066
-
Piloting a surveillance system for HIV drug resistance in the European Union. Euro Surveill. 2019 May; 24(19).
Score: 0.066
-
Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir. J Antimicrob Chemother. 2018 10 01; 73(10):2716-2720.
Score: 0.064
-
Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing. J Antimicrob Chemother. 2018 09 01; 73(9):2485-2492.
Score: 0.063
-
Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study). J Antimicrob Chemother. 2018 08 01; 73(8):2147-2151.
Score: 0.063
-
High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort. J Antimicrob Chemother. 2018 06 01; 73(6):1665-1671.
Score: 0.062
-
Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants. PLoS One. 2018; 13(6):e0198334.
Score: 0.062
-
Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals. Clin Infect Dis. 2018 05 17; 66(11):1785-1793.
Score: 0.062
-
Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen. Clin Infect Dis. 2018 05 02; 66(10):1588-1594.
Score: 0.062
-
Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine. Eur J Clin Pharmacol. 2018 Apr; 74(4):473-481.
Score: 0.061
-
No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir. J Antimicrob Chemother. 2018 Jan 01; 73(1):173-176.
Score: 0.060
-
Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients. J Antimicrob Chemother. 2017 10 01; 72(10):2954-2955.
Score: 0.059
-
HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors. J Antimicrob Chemother. 2017 09 01; 72(9):2431-2437.
Score: 0.059
-
Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma. J Antimicrob Chemother. 2017 08 01; 72(8):2351-2354.
Score: 0.059
-
Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study. J Antimicrob Chemother. 2017 06 01; 72(6):1769-1773.
Score: 0.058
-
Disparities in HIV-1 transmitted drug resistance detected by ultradeep sequencing between men who have sex with men and heterosexual populations. HIV Med. 2017 10; 18(9):696-700.
Score: 0.058
-
Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study. J Antimicrob Chemother. 2017 04 01; 72(4):1137-1146.
Score: 0.057
-
Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial. Antimicrob Agents Chemother. 2013 May; 57(5):2265-71.
Score: 0.043
-
New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T). Chem Biol Drug Des. 2019 01; 93(1):50-59.
Score: 0.016
-
Exploration of the effect of sequence variations located inside the binding pocket of HIV-1 and HIV-2 proteases. Sci Rep. 2018 04 10; 8(1):5789.
Score: 0.015
-
Efficiency of HIV-2 cultures from clinical isolates is enhanced after purification by anti-CD44 microbeads. J Virol Methods. 2018 07; 257:12-15.
Score: 0.015
-
Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort. J Antimicrob Chemother. 2017 06 01; 72(6):1745-1751.
Score: 0.014